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Robust hematopoietic specification requires 
the ubiquitous Sp1 and Sp3 transcription 
factors
Jane Gilmour1†, Leigh O’Connor1†, Christopher P. Middleton1,2†, Peter Keane1, Nynke Gillemans3, 
Jean‑Baptiste Cazier2, Sjaak Philipsen3  and Constanze Bonifer1*
Abstract 
Background: Both tissue‑specific and ubiquitously expressed transcription factors, such as Sp‑family members, are 
required for correct development. However, the molecular details of how ubiquitous factors are involved in pro‑
gramming tissue‑specific chromatin and thus participate in developmental processes are still unclear. We previously 
showed that embryonic stem cells lacking Sp1 DNA‑binding activity  (Sp1ΔDBD/ΔDBD cells) are able to differentiate into 
early blood progenitors despite the inability of Sp1 to bind chromatin without its DNA‑binding domain. However, 
gene expression during differentiation becomes progressively deregulated, and terminal differentiation is severely 
compromised.
Results: Here, we studied the cooperation of Sp1 with its closest paralogue Sp3 in hematopoietic development and 
demonstrate that Sp1 and Sp3 binding sites largely overlap. The complete absence of either Sp1 or Sp3 or the pres‑
ence of the Sp1 DNA‑binding mutant has only a minor effect on the pattern of distal accessible chromatin sites and 
their transcription factor binding motif content, suggesting that these mutations do not affect tissue‑specific chroma‑
tin programming. Sp3 cooperates with  Sp1ΔDBD/ΔDBD to enable hematopoiesis, but is unable to do so in the complete 
absence of Sp1. Using single‑cell gene expression analysis, we show that the lack of Sp1 DNA binding leads to a 
distortion of cell fate decision timing, indicating that stable chromatin binding of Sp1 is required to maintain robust 
differentiation trajectories.
Conclusions: Our findings highlight the essential contribution of ubiquitous factors such as Sp1 to blood cell devel‑
opment. In contrast to tissue‑specific transcription factors which are required to direct specific cell fates, loss of Sp1 
leads to a widespread deregulation in timing and coordination of differentiation trajectories during hematopoietic 
specification.
Keywords: Blood cell development, ATAC‑seq, Single‑cell RNA‑seq, Embryonic development, Differentiation 
trajectories, Transcription factor cooperation
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Background
The interaction of transcription factors (TFs) with chro-
matin drives the cooperation of distal elements with pro-
moters and directs cell fate choices in a developmental 
context. Tissue-specific gene activity is mostly driven by 
distal elements such as enhancers bound by tissue-spe-
cific factors, and their activity strongly correlates with 
gene expression  patterns. In contrast, promoter ele-
ments, in particular CG island promoters, are enriched 
for motifs of ubiquitously expressed factors such as NFY 
or Sp1 and do not show such strict correlation [1]. More-
over, distal elements can be activated at the chromatin 
level prior to the onset of gene expression, and subse-
quently drive tissue-specific gene activity by interaction 
with the generic factors bound to promoters [2]. How-
ever, the precise role of ubiquitously expressed TFs in the 
regulation of tissue-specific gene expression is not well 
understood.
Sp1 was the first identified member of a large family of 
zinc finger transcription factors recognising the GC and 
GT box DNA elements with binding sites in  vivo being 
enriched for CG island promoters [3–6]. Both Sp1 and 
the closely related family member Sp3 are ubiquitously 
expressed and recognise the same DNA-binding motifs. 
Sp1 DNA binding is indispensable for normal mamma-
lian embryo development, since mice expressing a trun-
cated version of Sp1 lacking the DNA-binding domain 
(DBD)  (Sp1ΔDBD/ΔDBD) demonstrate multiple heteroge-
neous phenotypic abnormalities and die in utero [7]. 
It was not possible to identify a specific role of Sp1 in a 
specific pathway by conditional deletion, as no defects 
were observed when the gene was deleted at later stages 
of development [3] (unpublished results), indicating that 
the developmental defects in  Sp1ΔDBD/ΔDBD mice were 
cumulative.  Sp3−/− mice with a complete gene knockout 
survive until birth but die shortly after due to respiratory 
failure [8]. Additional  studies in Sp3-null mice provided 
evidence of defects in hematopoiesis and a requirement 
for Sp3 in normal cardiac development [9, 10].  Sp1+/
ΔDBD/Sp3+/− compound heterozygous mice also showed 
embryonic lethality but survived until later in develop-
ment than  Sp1ΔDBD/ΔDBD mice [11]. Therefore, while there 
may be some functional redundancy, tightly regulated 
levels of both factors are required throughout normal 
embryogenesis. However, the extent of the cooperativity 
of these two proteins at the genomic level has not been 
fully resolved. In addition, it is unknown whether in the 
absence of the DBD, the Sp1 protein is capable of stable 
interaction with the genome.
Sp3 has been described as a repressor of Sp1 transacti-
vation and was proposed to exert this effect by competing 
for the Sp binding motif, since Sp3 lacking a DNA-bind-
ing domain could not inhibit Sp1 activity [12]. However, 
Sp3 has been shown to have transactivation potential, 
and several studies have demonstrated synergistic acti-
vation of target genes by Sp1 and Sp3 [5, 13, 14]. Volkel 
et  al. [15] found that binding of Sp1 and Sp3 in mouse 
embryonic fibroblasts (MEFs) largely overlapped and 
binding was predominantly at promoter sites with con-
ventional GC box motifs. Differences in the ability of Sp1 
and Sp3 to bind to multiple GC boxes may contribute to 
their capacity to activate or repress at different binding 
sites [16, 17]. The issue of co-localisation is still not clear 
as He et al. [18] demonstrated localisation of the two pro-
teins to different nuclear compartments in MCF7 cells.
To be able to conduct genome-wide binding studies 
and to bypass the problems with embryonic lethality in 
mice, we used in  vitro differentiation of mouse embry-
onic stem cells (ESC) into blood cells as a tractable model 
to shed light on the role of Sp1 in the control of  devel-
opmental gene expression. We previously showed that 
 Sp1ΔDBD/ΔDBD cells are unable to terminally differentiate 
and that this phenotype was associated with a progres-
sive deregulation in gene expression [3]. In the present 
study, we aimed to investigate (1) the phenotype of ESC 
with a complete knockout of Sp1, (2) the ability of Sp3 
to compensate for the absence/dysfunction of Sp1 and 
(3) whether the progressive deregulation of gene expres-
sion in differentiating  Sp1ΔDBD/ΔDBD cells was due to het-
erogeneity of gene expression within cells or a failure of 
executing cell fate decisions. Our results demonstrate 
that Sp1 and Sp3 binding sites strongly overlap and that 
the  Sp1ΔDBD/ΔDBD protein partially retains Sp1 function. 
While Sp3 can compensate for Sp1 binding at some tar-
get genes, it cannot support hematopoietic specification 
alone, and Sp3-null ESC also have a defect in myeloid 
differentiation. Most importantly, we show by single-cell 
RNA sequencing that the differentiation trajectory lead-
ing to hematopoietic differentiation is severely disturbed 
in  Sp1ΔDBD/ΔDBD cells. Cells execute the order of cell fate 
decisions correctly, but not as a cohort and with delayed 
kinetics, indicating that Sp1 is required for executing a 
robust differentiation program.
Results
The complete knockout of Sp1 is incompatible 
with hematopoietic specification but does not lead 
to widespread changes in chromatin accessibility
Using an in  vitro hematopoietic differentiation system 
[19, 20] (Fig. 1a), we previously demonstrated that murine 
E14 ESC lacking the DBD of Sp1 (E14  Sp1ΔDBD/ΔDBD) 
show a defect in macrophage differentiation. We show 
here that these cells also have a reduced capacity to gen-
erate Flk1 + hemangioblast cells (Fig. 1b) [3]. We applied 
CRISPR-Cas9 gene editing using guide RNAs targeting 
the DBD of Sp1 encoded by exons 5 and 6 to recapitulate 
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this defect in a different ES cell type (A17 2Lox cells) [21, 
22] (Additional file 1: Fig. S1a). Gene editing generated a 
clone (A17Lox  Sp1ΔDBD/ΔDBD) that expressed a low level 
of the truncated version of Sp1 in the absence of the full-
length protein (Additional file 1: Fig. S1b and S1c, clone 
4). Three heterozygous clones expressing wild-type levels 
of Sp1 were also identified along with a clone completely 
lacking Sp1 protein expression (Additional file 1: Fig. S1b 
and S1c, clone 14). Further analysis of clone 14 revealed 
an out of frame mutation at the cut site in exon 5 (Addi-
tional file 1: Fig. S1a), which probably caused RNA deg-
radation by nonsense-mediated decay, resulting in a 
 Sp1−/− phenotype.
We next evaluated the effect of CRISPR deletion in 
the A17Lox  Sp1ΔDBD/ΔDBD and A17Lox  Sp1–/− clones in 
the in  vitro differentiation system and in macrophage 
release assays. As found with E14  Sp1ΔDBD/ΔDBD cells, 
A17Lox  Sp1ΔDBD/ΔDBD cells had a significantly reduced 
capacity to generate Flk1 + cells from embryoid bod-
ies (EB) while A17Lox  Sp1−/− cells   produced  even 
lower levels of Flk1 + cells  (Additional file 1: Fig. S1d). 
Heterozygous clones generated wild-type numbers  of 
macrophage-releasing EBs, whereas EBs from A17Lox 
 Sp1ΔDBD/ΔDBD and A17Lox  Sp1−/− clones had sig-
nificantly lower capacity to generate macrophages 
with  the severest phenotype exhibited by the cells car-
rying a complete knockout of Sp1 (clone 14, Fig.  1c). 
To verify that the reduced Flk1 expression and mac-
rophage production were a direct result of Sp1 disrup-
tion and not a result of off-target CRISPR effects, we 
rescued the phenotype by expressing human wild-type 
Sp1 (Additional file 1: Fig. S1e) and restored increased 
levels of Flk1 + expression as detected by FACS analy-
sis (Fig.  1d). These data demonstrate that a complete 
lack of Sp1 is incompatible with the differentiation of 
ESC and that the truncated version of Sp1 lacking DNA 
binding is a hypomorph that partly retains normal Sp1 
function.
To examine whether the decreased differentiation 
potential in the Sp1-disrupted clones was a result of 
changes in chromatin accessibility caused by a lack of 
Sp1 binding, we employed the genome-wide Assay for 
Transposase-Accessible Chromatin using sequenc-
ing (ATAC-seq) [23]. We found a high degree of cor-
relation in DNA accessibility between the A17Lox WT, 
heterozygous and Sp1-disrupted clones (Fig.  1e). Only 
around 400 accessible chromatin sites were either lost 
or gained between the A17Lox WT cells and either 
A17Lox  Sp1ΔDBD/ΔDBD or A17Lox  Sp1−/− clones sug-
gesting that lack of Sp1 does not result in widespread 
changes in chromatin accessibility in ESC (Fig.  1f ). In 
addition, we confirmed similarity in hypersensitive 
site profiles between the A17Lox WT cells and the E14 
WT cells used in the original study (Additional file  1: 
Fig.  S1f ), confirming that this phenotype was not cell 
clone dependent. Finally, chromatin accessibility clus-
tered by cell type rather than by Sp1 binding capac-
ity when we compared ESC and Flk1 + differentiation 
stages (Additional file  1: Fig.  S1g), indicating that the 
developmentally regulated activation and silencing of 
active cis-regulatory elements which exists as accessi-
ble chromatin sites was not affected by the absence of 
Sp1. While there were some sites such as an intronic 
region of the Ostm1 gene that displayed a loss of acces-
sibility specifically in the Sp1-disrupted clones (Addi-
tional file  1: Fig.  S1h), the vast majority of accessible 
sites were unaffected as observed at the Pou5f1 locus 
(Additional file 1: Fig. S1i).
Sp3 partially compensates for Sp1 in cells with disrupted 
Sp1 DNA binding
Our finding of a residual activity of the  Sp1ΔDBD/ΔDBD pro-
tein suggested that it may be able to interact with chro-
matin via other factors, similar to what has been found 
for SCL/TAL1 [24]. We therefore examined the Sp1 chro-
matin binding in the A17Lox  Sp1ΔDBD/ΔDBD clone and 
the A17Lox  Sp1−/− control clone using global chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) 
assays. We used a double crosslinking method of fixation 
to capture any Sp1 protein that was not directly bound to 
DNA. Neither clone showed significant levels of binding 
in either ESC or in Flk1 + cells (Fig.  2a), demonstrating 
Fig. 1 The complete absence or the truncation  of Sp1 do not cause widespread changes in chromatin accessibility. a Schematic representing 
in vitro differentiation of ESC. b FACS analysis of Flk1 expression in E14 WT and E14  Sp1ΔDBD/ΔDBD cells derived from embryoid bodies (EB) at day 
3.25 of in vitro differentiation. Left panel: representative FACS profiles for Flk1‑PE staining, right panel: graph showing Flk1 expression and isotype 
controls for E14 WT and  Sp1ΔDBD/ΔDBD cells (n = 4, **indicates p < 0.001). c Graph showing the percentage of EB releasing macrophages in a 
macrophage release assay (n = 3, * indicates p < 0.05). d Rescue of Flk1 expression levels by re‑expression of wild‑type Sp1 in  Sp1−/− and  Sp1ΔDBD/
ΔDBD cells (n = 3 for  Sp1−/− and n = 4 for  Sp1ΔDBD/ΔDBD, p values are indicated on the graph). e Pearson correlation plot of accessible chromatin 
regions in ESC as determined by ATAC‑seq, in WT cells and Sp1 mutant ESC clones. f Heat maps showing the fold difference in accessible chromatin 
sites, as determined by ATAC, between WT and  Sp1ΔDBD/ΔDBD E14 ESC (left panel) and WT and  Sp1−/− A17Lox ESC (right panel). The red box indicates 
WT‑specific ATAC sites, while the blue box indicates ATAC sites specific to either  Sp1ΔDBD/ΔDBD or  Sp1−/− cell lines
(See figure on next page.)
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that in spite of its functional activity, the truncated Sp1 
protein does not stably interact with chromatin.
To compare the binding of Sp3 with that of Sp1, we 
performed ChIP-seq for Sp1 and Sp3 in WT A17Lox 
cells and A17Lox Sp1-disrupted clones. We gener-
ated high confidence ChIP-seq peaks for both factors 
in both ESC and Flk1+ cells by overlapping them with 
ATAC-seq peaks (Additional file  1: Fig.  S2a). We also 
compared Sp1/3 binding to publicly available data-
sets to examine whether Sp1/3 factors cooperate with 
other factors or associate with specific histone modifi-
cation patterns (Table  S1). In A17Lox WT cells, there 
was a strong overlap in binding sites for Sp1 and Sp3, 
although there were also unique sites, particularly for 
Sp3 (Fig.  2b, Additional file  1: Figs.  S2b and S2c). Sp1 
and Sp3 binding occurred at regions of active chromatin 
as evidenced by the co-occurrence of histone modifica-
tions such as H3K27Ac and H3K4me3 and the absence 
of H3K27me3 (Fig.  2b). Sp, NFY and YY1 motifs were 
enriched at shared Sp1/Sp3 binding sites, and corre-
sponding binding of NFY and YY1 at overlapping sites 
in ESC was observed. Interestingly, we saw enrichment 
of CTCF motifs and binding at sites which preferentially 
bound Sp3 but not Sp1. With the exception of Oct4, 
pluripotency factor binding was not strongly enriched 
at sites of Sp1/Sp3 binding in ESC (Fig. 2b). In ESC, Sp1 
was evenly distributed between promoter and distal 
sites, while Sp3 was located at a slightly higher number 
of distal sites (Additional file 1: Fig. S2d). In Flk1+ cells, 
promoter occupancy increased slightly for both factors 
(Additional file 1: Fig. S2d).
Comparison of Sp1 and Sp3 binding patterns revealed 
almost 20,000 shared sites in ESC (Fig. 2c). Sp1 showed 
a greater than twofold enriched binding compared to Sp3 
at 1975 unique sites, while Sp3 occupied 3228 unique 
sites. The distribution of Sp1/Sp3 peaks was similar in 
Flk1 + cells; however, fewer Sp1-specific peaks were 
observed (873, Fig.  2d). Shared and Sp1-specific peaks 
had higher enrichment for NFY motifs in both ESC and 
Flk1 + cells, whereas Sp3-specific peaks showed prefer-
ential enrichment for CTCF and ETS motifs and surpris-
ingly, an absence of Sp motifs (Additional file 1: Fig. S2e, 
S2f, S2g, S2h). We and others previously showed that Sp1 
binding is enriched at CG islands [3, 15] and Sp1 can bind 
at multiple motifs in a regulatory region [25]. To exam-
ine how Sp1 and Sp3 could co-localise, we mapped the 
number of motifs within peaks in shared and Sp1-specific 
peaks (Fig. 2g, h, Additional file 1: Fig. S2i, S2j). In keep-
ing with our previous finding, promoter peaks contained 
a high frequency of multiple motifs, whereas distal peaks 
were more likely to have no motif or low numbers of 
motifs, particularly in Flk1+ cells.
To gain insight into the cooperation of Sp1 and Sp3, we 
investigated the effect of the lack of Sp1 on Sp3 binding. 
In general, the absence or mutation of Sp1 had no global 
effect on the binding of Sp3 (Fig.  2c), demonstrating 
that binding is not absolutely interdependent. However, 
we detected a few sites that acquired Sp3 binding in the 
Sp1-disrupted clones (Fig. 2e). To uncover such sites, Sp3 
binding at Sp1-specific peaks was re-ranked according to 
the strength of Sp3 binding in WT cells and we found 650 
newly acquired peaks in the  Sp1ΔDBD/ΔDBD  cells and 595 
newly acquired peaks in the  Sp1−/− cells  (Fig.  2e). This 
(See figure on next page.)
Fig. 2 Sp3 partially compensates for the absence of Sp1 in cells with disrupted Sp1 binding. a Average profiles of Sp1 ChIP enrichment in ESC 
(left panel) and Flk1+ cells for WT and CRISPR clones. b Heat maps showing a ranking of normalised tag counts from Sp1 ChIP‑seq in A17Lox 
WT ES cells. Ranked alongside are tag counts from the Sp3 ChIP‑Seq in the same cells and motifs for CTCF, NFY, YY1, ESRRB, NANOG, OCT4 and 
SOX2. Heat maps (public datasets, see Additional file 1: Table 1) showing ChIP‑seq enrichment for CTCF, NFY, YY1, ESRRB, NANOG, OCT4 and SOX2. 
The histone modifications H3K9Ac, H3K27me3, H3K4me3 and H3K27Ac are shown alongside. c Heat maps showing fold difference in ChIP‑seq 
enrichment between Sp1 and Sp3 ChIP in E14 WT ES cells. Ranked along the same coordinates are Sp1 and Sp3 ChIP tag counts in  Sp1ΔDBD/ΔDBD 
and  Sp1−/−  cells. Peaks were classed as specific if they showed equal to or more than twofold change in tag count difference between the Sp1 and 
Sp3 ChIPs. The specific and shared groups are indicated by coloured bars alongside (red indicates Sp1 specific peaks and blue indicates Sp3 specific 
peaks), and the number of peaks within each group is shown. d Heat maps showing fold difference in ChIP‑seq tag count enrichment between Sp1 
and Sp3 ChIP peaks in Flk1+ cells. Ranked along the same coordinates are Sp1 and Sp3 ChIP in  Sp1ΔDBD/ΔDBD  cells. Peaks were classed as specific 
if they showed more than twofold change in tag count difference between the Sp1 and Sp3 ChIPs. The specific and shared groups are indicated 
by coloured bars alongside (red indicates Sp1 specific peaks and blue indicates Sp3 specific peaks), and the number of peaks within each group is 
shown. e Zoomed‑in heat map of the 1975 Sp1 specific sites in ESC shown in Fig. 2c. Right‑hand panels show the Sp3 ChIP‑seq enrichment ranked 
according to the changes in Sp3 occupancy at these sites in  Sp1ΔDBD/ΔDBD and  Sp1−/−  cells. The blue bar indicates peaks which are increased in 
the mutant cell lines compared to WT, and the green bar indicates peaks which are reduced at least twofold in the mutant cell lines compared to 
WT. f Zoomed‑in heat map of 873 Sp1 specific sites in Flk1+ cells shown in Fig. 2d. Right‑hand panel shows the Sp3 ChIP‑seq enrichment ranked 
according to the changes in Sp3 occupancy at these sites. The blue bar indicates peaks which are increased in the mutant cell lines compared to 
WT, and the green bar indicates peaks which are reduced at least twofold in the mutant cell lines compared to WT. g Bar graphs indicating numbers 
of motifs within the 1975 Sp1 specific peaks in ESC. Separate graphs show all peaks, distal peaks and promoter peaks. The number of peaks is 
indicated above each bar. h Bar graphs indicating numbers of motifs within the 873 Sp1 specific peaks in Flk1+ cells. Separate graphs show all 
peaks, distal peaks and promoter peaks. The number of peaks is indicated above each bar
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effect was less pronounced in Flk1 + cells with only 57 
newly acquired peaks in the  Sp1ΔDBD/ΔDBD cells (Fig. 2f ). 
This result would suggest that in ESC, Sp3 can compen-
sate for loss of Sp1 at a subset of binding sites but this 
effect may not be maintained throughout differentiation 
since fewer sites in Flk1+ cells acquired de novo Sp3 
binding in the absence of Sp1.
Sp1 and Sp3 mutant ESC exhibit common and unique 
features during hematopoietic differentiation
We next investigated the contribution of Sp1 and 
Sp3 to hematopoietic specification (Fig.  3) and gene 
expression (Fig.  4). Although Sp1 and Sp3 share the 
majority of their binding sites as exemplified at the Sp1 
locus, they also demonstrate specific binding (Fig. 3a, 
top panel). The gene encoding zinc finger domain-con-
taining protein Zswim6 has a shared Sp1/Sp3 site at 
the promoter in addition to an intergenic Sp1-specific 
peak, whereas the Yod1 deubiquitinase gene has a Sp3-
specific peak at the promoter. Since Sp3 appeared to 
compensate at some but not all Sp1 binding sites in the 
absence of Sp1 (Fig.  2e), we examined in more detail 
how blood cell development from ESC was affected 
in the absence of Sp3. Using an E14 ESC line lacking 
Sp3 [8] (Additional file 1: Figs. S3a, b), we found that 
these cells  generate a reduced number of Flk1+ cells 
after 3.25 days of EB formation (Fig. 3b), although the 
phenotype was less pronounced when compared with 
 Sp1ΔDBD/ΔDBD and  Sp1−/− cells (Fig. 1). Sp3−/− Flk1+ 
cells produced more Kit-expressing cells in blast cul-
ture but showed similar proportions of hemogenic 
endothelium (HE) and progenitors compared to WT 
cells (Fig.  3b, d; Additional file  1: Fig.  S3d). In com-
mon with E14  Sp1ΔDBD/ΔDBD ESC  (Fig.  1), E14  Sp3−/− 
ESC showed defective macrophage production in 
macrophage release assays (Fig.  3e, Additional file  1: 
Fig. S3d). 
Production of primitive erythrocytes was severely 
impaired in E14  Sp3−/− cells compared to WT cells 
(Fig. 3f ), whereas we previously found that E14  Sp1ΔDBD/
ΔDBD ESC showed only  delayed production of primitive 
erythrocytes [3]. We attempted to produce an ES cell 
line with inducible Cre-responsive conditional deletion 
of both Sp3 and the Sp1 DBD. A mouse carrying these 
alleles shows severe macrothrombocytopenia after mega-
karyocyte-specific deletion of these genes [26]. In spite of 
multiple attempts, we did not obtain any clones carrying 
both deletions, indicating that ESC maintenance requires 
the presence of intact versions of either Sp1 or Sp3, again 
demonstrating that the extent of requirement for Sp1/
Sp3 proteins is developmental stage specific with defects 
being more severe at early developmental stages.
To investigate whether the mutation of Sp1 and Sp3 
differentially affected gene expression at the various 
developmental stages, we performed RNA-seq with 
E14 ESC, as well as with sorted Flk1+ , HE1, HE2 and 
progenitor cells from E14 WT, E14  Sp1ΔDBD/ΔDBD and 
E14  Sp3−/− cells (Additional file 1: Fig. S4a). Hierarchi-
cal clustering of the  row Z scores from all expressed 
genes revealed the expected dynamic changes in gene 
expression across the differentiation stages for all cell 
lines (Additional file  1: Fig.  S4b). This result indicates 
that the majority of differentiation-associated gene 
expression changes were unaffected by the mutations. 
To examine genes whose expression levels were dif-
ferentially affected between WT cells and either E14 
 Sp1ΔDBD/ΔDBD or E14  Sp3−/− cells in at least one of the 
differentiation stages (Additional file  1: Fig.  S4c, S4d), 
we used covariance analysis (Fig.  4a and Additional 
file  2: Dataset 1 for gene lists). Representative genes 
from each cluster are shown (Fig.  4b). These patterns 
of expression clustered together irrespective of the cell 
line, and average gene expression across clusters was 
again broadly similar between the cell lines (Additional 
file 1: Fig. S4b). However, this was not true for all genes. 
Within cluster 1, a sub-cluster of 92 genes showed 
increased expression in the  Sp3−/− cells compared to 
WT and  Sp1ΔDBD/ΔDBD cells (Additional file  2: Data-
set 1 for gene lists). Within cluster 4, 35 genes showed 
reduced expression in  Sp1ΔDBD/ΔDBD cells  relative to 
both WT and  Sp3−/− cells (Additional file 1: Fig. S4e).
To examine the direction of cell type-specific gene 
expression changes in the different types of mutant ESC 
or Flk1+ cells in more detail, we grouped genes according 
to whether they were up- or down-regulated at least two-
fold in either E14  Sp1ΔDBD/ΔDBD or E14  Sp3−/− cells com-
pared to E14 WT cells  (Fig.  4c, d and Additional file  3: 
Dataset 2). Cells were separated into 8 different groups 
for each cell type. Despite the large overlap in DNA-bind-
ing sites (Fig. 2), Sp1 and Sp3 mutant ESC showed mostly 
independent gene expression changes, with only a few 
shared up- and down-regulated genes (Fig. 4c, d, Groups 
1 and 8). Very few genes showed completely reciprocal 
changes in expression when compared with WT (Fig. 4c, 
d, Groups 4 and 5). The majority of deregulated genes 
were targets of both Sp1 and Sp3 with only a minority of 
genes being unique Sp1 or Sp3 targets (Additional file 1: 
Fig. S4f, S4g).
In summary, these results demonstrate that (1) the 
overall cell differentiation trajectory up to the progenitor 
stage is largely unaffected in  Sp1ΔDBD/ΔDBD and  Sp3−/− 
cells, and (2) the interplay of Sp1 and Sp3 at shared 
sites is context dependent with only a small proportion 
of genes changing expression the same direction in the 
absence of either Sp1 or Sp3.
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Fig. 3 Sp3−/− ES cells exhibit a defect in hematopoietic differentiation. a Genome browser screenshots depicting examples of shared and unique 
binding sites. Top panel: Sp1 is an example of an Sp1/Sp3 shared promoter binding site; middle panel: Zswim6 is an example of an intragenic Sp1 
specific peak (highlighted by the red box); bottom panel: Yod1 is an example of an Sp3 specific promoter peak (highlighted by the blue box). b 
Flk1 FACS staining on WT and  Sp3−/− cells at day 3.25 of EB differentiation (n = 5, **indicates p < 0.01). c Kit FACS staining of WT and  Sp3−/− cells at 
day 2 of blast culture (n = 4, *indicates p < 0.05). d Percentage cell populations from WT and  Sp3−/− cells at day 2 of blast culture (n = 4, n.s. indicates 
not statistically significant). e Percentage of macrophage‑releasing EB in a macrophage release assay comparing WT and  Sp3−/− cells (n = 4, 
*indicates p < 0.05). f Number of primitive erythroid colonies in an EryP colony formation assay comparing WT and  Sp3−/− cells (n = 4, *indicates 
p < 0.05)
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Single‑cell RNA‑seq analysis reveals  a deviation 
from normal differentiation patterns in  Sp1ΔDBD/ΔDBD blast 
culture cells
Our previous gene expression microarray analysis of the 
effect of the E14  Sp1ΔDBD/ΔDBD mutation on gene expres-
sion showed that it was progressively deregulated com-
pared to WT cells as differentiation progressed, with 
more and more genes displaying perturbed expression 
[3]. Interestingly, when we subjected these data to a prin-
cipal component analysis, we noticed that the data from 
E14  Sp1ΔDBD/ΔDBD cells showed the same differentiation 
trajectory up to progenitor cells, but were characterised 
by a third, unknown component. This was confirmed 
when we used RNA-seq and unbiased clustering analy-
sis (Additional file 1: Fig. S5A, data not shown). We next 
investigated the nature of this third component. How-
ever, a significant problem with the analysis of bulk cell 
populations is that it is possible to obtain trends in gene 
expression, but even with FACS-sorted populations there 
can be significant cellular heterogeneity. It was therefore 
unclear whether the progressive deviation in gene expres-
sion was a faithful reflection of the expression pattern 
within individual cells, or a consequence of increased cel-
lular heterogeneity within the sorted populations.
To answer this question, we used the  10x  Genom-
ics Chromium single-cell RNA-seq system to investi-
gate the heterogeneity in gene expression in day 2 blast 
cultures obtained from E14 WT and E14  Sp1ΔDBD/ΔDBD 
ESC. At this developmental stage, we can isolate cells 
representing multiple differentiation stages from the 
same culture. Cells were sorted for surface Kit expres-
sion prior to loading cells on the instrument (Additional 
file  1: Fig.  S5b). Sequencing data from more than 2000 
cells for each sample were used for downstream analysis 
(Additional file  1: Fig.  S5c). We used t-distributed sto-
chastic neighbour embedding (t-SNE) analysis to visu-
alise clusters with similar gene expression profiles from 
E14 WT and E14  Sp1ΔDBD/ΔDBD cells (Fig. 5a). Four dis-
tinct clusters were identified in both samples with the 
help of typical marker genes listed in Additional file  4: 
Dataset 3, resembling early progenitor cells (green), 
erythroid cells (red), endothelial cells (purple) and epi-
thelial-like cells of unknown origin (blue). However, an 
additional megakaryocytic cluster was found in the E14 
 Sp1ΔDBD/ΔDBD cell population (orange), and the other 
clusters displayed different shapes. A heat map showing 
the specificity of marker genes for each individual cluster 
is shown in Additional file  1: Fig.  S5d. Gene expression 
for a selection of these markers was mapped onto the 
cell clusters (Fig.  5b). For example, Cd34 was predomi-
nantly expressed in the cluster resembling stem and early 
precursor cells, whereas Hba-X was mainly expressed in 
erythroid cells and an increased number of E14  Sp1ΔDBD/
ΔDBD cells expressed the megakaryocyte marker Gp1bb   
(Fig. 5b).
We next performed differential gene expression anal-
ysis to explore in more detail the differences behind 
the deregulation of E14  Sp1ΔDBD/ΔDBD differentiation. 
t-SNE plots showing both E14 WT and E14  Sp1ΔDBD/
ΔDBD cells were coloured according to the genotype of 
the cell line (Fig. 6a, left panel) or according to cell type 
cluster (Fig.  6a, right panel), illustrating the spread of 
the individual cells across the different clusters. These 
results also demonstrate that genes specific for particu-
lar cell types are expressed in the relevant cluster and 
that the same clusters are present in WT and mutant 
cells (Fig. 6b). We then overlaid the relative gene expres-
sion for selected differentially expressed genes onto these 
plots thus allowing us to visualise the extent of variation 
of an individual gene between the cell lines across the 
different clusters; several examples are shown in Fig. 6b 
and Additional file 1: Fig. S6b. One example is the growth 
factor Midkine (Mdk) which was found to be an Sp1 tar-
get in human glioma cells [27], and from our single cell 
data showed substantial down-regulation across all E14 
 Sp1ΔDBD/ΔDBD cell clusters, although some individual cells 
retained strong expression particularly in epithelial cells. 
Normalised FPKM values from RNA-seq of the bulk pop-
ulations demonstrated only a modest down-regulation of 
Mdk at all stages except ESC highlighting the importance 
(See figure on next page.)
Fig. 4 Deregulated gene expression in  Sp1ΔDBD/ΔDBD and  Sp3−/− cell populations. a Hierarchical clustering of differentially regulated genes 
between WT,  Sp1ΔDBD/ΔDBD and  Sp3−/− cell populations from each stage of the differentiation series according to the row Z score. Data were 
separated into 13 clusters, and the number of the cluster is shown to the left of the heat map. Representative genes from each cluster are shown to 
the right of the heat map. b Box plots representing the Z score of gene expression of each individual cluster from (a). c Heat map representing the 
grouping analysis of differentially regulated genes for  Sp1ΔDBD/ΔDBD relative to WT and  Sp3−/− relative to WT in ESC. The coloured sidebar indicates 
the 8 clusters assigned according to the changes in gene expression. GO terms for selected groups are shown to the left of the heat map. The table 
beneath shows the number of deregulated genes in each group and the number of Sp1 and Sp3 target genes within each cluster. d Heat map 
representing the grouping analysis of differentially regulated genes for  Sp1ΔDBD/ΔDBD relative to WT in Flk1+ cells, and  Sp3−/− relative to WT in Flk1+ 
cells. The coloured sidebar indicates the 8 clusters assigned according to the changes in gene expression. GO terms for selected groups are shown 
to the left of the heat map. The table beneath shows the number of deregulated genes in each group and the number of Sp1 and Sp3 target genes 
within each cluster
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Fig. 5 Identification of different cell populations in differentiating WT and  Sp1ΔDBD/ΔDBD cells. a t‑SNE visualisation of the indicated cell populations 
within  Sp1ΔDBD/ΔDBD Kit+ sorted cells from day 2 of blast culture. The left panel shows WT cells; right panel shows  Sp1ΔDBD/ΔDBD cells. Each dot 
represents the transcriptome of a single cell, colour coded according to the assigned cellular identity as shown to the right of the panels. b 
Expression of selected marker genes superimposed onto the different clusters for WT and  Sp1ΔDBD/ΔDBD cells
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of single-cell data to uncover such differences (Additional 
file  1: Fig. S6c). Mdk has been proposed as a regulator 
of the epithelial–mesenchymal transition (EMT) during 
mouse embryogenesis. Furthermore, it  has been impli-
cated in Notch signalling pathways and as an antagonist 
of vascular endothelial growth factor (VEGF) suggesting 
that it may play a role in development [28–30]. Cysteine-
rich intestinal protein 1 (Crip1) was also proposed as a 
mediator of EMT, in this case in human cervical carci-
noma via the Wnt signalling pathway [31]. We found that 
expression of Crip1 was strongly down-regulated in E14 
 Sp1ΔDBD/ΔDBD cells, particularly in endothelial and epithe-
lial clusters (Fig. 6b). This finding correlated with changes 
seen in the bulk RNA-seq data, and interestingly, differ-
ences in Crip1 gene expression were evident as early as 
the ESC stage of development (Additional file 1: Fig. S6c). 
Klf2 is expressed in murine vascular endothelial cells dur-
ing early embryogenesis, and mice lacking Klf2 display 
compromised vascular integrity and die in utero as a 
result of haemorrhage [32]. E14  Sp1ΔDBD/ΔDBD endothelial 
cells show reduced expression of Klf2 suggesting a poten-
tial defect in the formation or function of the hemogenic 
endothelium (Fig.  6b). A comparison of genes deregu-
lated in E14  Sp1ΔDBD/ΔDBD in Kit + day 2 of blast cul-
ture cell populations with Sp1 target genes in ESC and 
Flk1+ cells indicates that a proportion of the genes were 
already Sp1 targets early in development (Fig.  6c). In 
summary, these results confirm that while differentiation 
can progress in E14  Sp1ΔDBD/ΔDBD cells, normal Sp1 func-
tion is required to maintain the proper timing of lineage 
specification.
Our cell populations represent a dynamic differentia-
tion system, and analysis of the single-cell transcriptome 
data allows inference of differentiation trajectories based 
on gene expression from individual cells. To this end, we 
performed pseudotime ordering to identify the trajectory 
of differentiation in E14 WT and E14  Sp1ΔDBD/ΔDBD cells. 
Here, individual cells are displayed along these trajecto-
ries based on the cluster they represent (Fig. 7a). In E14 
WT cells, cell clusters were associated with two distinct 
trajectories with cells following a hematopoietic and an 
endothelial differentiation trajectory which is expected 
for the mixed population of cells developing at this stage 
of differentiation [19]. In contrast, differentiation tra-
jectories in  Sp1ΔDBD/ΔDBD cells were strongly disordered 
with the direction of the trajectory for each cell fate deci-
sion being preserved, but with more branch points, indi-
cating that the timing of differentiation was  disturbed, 
thus explaining the third PCA component. In addition, 
we see an enhanced development of megakaryocytes. 
This type of disordered differentiation was confirmed 
when we overlaid the expression patterns of individual 
genes along the projected trajectories (Fig.  7b, Addi-
tional file  1: Fig.  S7a). For both cell lines, expression of 
Tal1 was widespread throughout all lineages but absent 
from epithelial-like cells, consistent with its known role 
in hemangioblasts and in blood formation [33]. Runx1 
was expressed in committed hematopoietic cells, and so 
was the RUNX1 target Spi1 in both E14 WT cells and 
E14  Sp1ΔDBD/ΔDBD cells. The TGFβ receptor component 
Endoglin (Eng) showed highest expression within the 
endothelial cell cluster, consistent with its role in the 
formation of both blood cells and blood vessels [34]. In 
 Sp1ΔDBD/ΔDBD cells, Eng expression was spread across 
multiple branch points with hematopoietic cells branch-
ing off. Taken together, our data show that Sp1 is not 
involved in cell fate decisions, but strongly influences at 
which time point cell fate decisions are executed.
Discussion
A large number of promoters and distal elements contain 
binding sites for two members of the Sp family of tran-
scription factors, Sp1 and Sp3. These proteins have been 
studied for decades, and their important role in devel-
opment has been established, but their precise function 
in regulating specific developmental pathways is still 
largely unknown. This study used systems-level analysis 
to address this issue and answer a number of fundamen-
tal questions of how Sp1 and Sp3 are involved in driving 
hematopoietic specification.
Sp1 and Sp3 cooperate to generate blood cells
Our study finds that both Sp1 and Sp3 are important 
for correct hematopoietic specification whereby the 
complete lack of Sp1 is incompatible with differentia-
tion. We show that the original Sp1 knockout [7] which 
introduced a truncated  Sp1ΔDBD/ΔDBD protein consti-
tutes a hypomorphic version of this factor with residual 
activity. The complete Sp3 knockout  (Sp3−/−) also has a 
blood differentiation phenotype and shares some features 
(See figure on next page.)
Fig. 6 Sp1ΔDBD/ΔDBD cells contain an additional megakaryocyte cluster as compared to WT cells. a t‑SNE visualisation of combined WT and  Sp1ΔDBD/
ΔDBD populations. Each dot represents a single cell. In the left panel, dots are coloured to represent the genotype as indicated. In the right panel, 
dots are coloured according to the cell identity as indicated. b The expression level of selected differentially expressed genes was superimposed 
onto the t‑SNE plots shown in Fig. 6a. Gene names are indicated to the right of the panel. c Venn diagrams representing the overlap between Sp1 
ChIP‑seq targets in ESC (light green circles) or Flk1+ cells (dark green circles) with up‑regulated genes (red circles) or down‑regulated genes (blue 
circles) determined from single‑cell differential gene expression analysis. The number of genes for each group is indicated
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of the Sp1 hypomorphic phenotype including reduced 
Flk1 expression and reduced macrophage production 
from EBs. However,  compared to  Sp1ΔDBD/ΔDBD  cells 
the phenotype is weaker which is in agreement with the 
observations in mice [8]. While the simultaneous muta-
tion of both Sp1 and Sp3 is incompatible with ESC main-
tenance, either is dispensable for the establishment of a 
correct, cell type-specific chromatin accessibility pat-
tern. This result demonstrates that cell fate decisions are 
not driven by Sp1 and Sp3 but by tissue-specific factors. 
The majority of Sp1 and Sp3 sites overlap, and with some 
exceptions, Sp3 binding is not dependent on the pres-
ence of Sp1. However, both proteins need to cooperate 
for normal development to occur, as shown by the abil-
ity of cells to differentiate up to a certain point when the 
 Sp1ΔDBD protein is present together with Sp3.
Previous studies provided some indications for such 
DBD-independent interactions between Sp-factors. The 
Sp family member Sp2 was found to bind to chromatin 
through association with NFY and independent of its 
Fig. 7 Absence of functional Sp1 results in highly disordered differentiation trajectories. a Pseudotime trajectory plots of WT and  Sp1ΔDBD/ΔDBD 
Kit + sorted cells from day 2 of blast culture. Each dot represents the transcriptome of a single cell, colour coded according to the assigned cellular 
identity as shown to the right of the panels. b Expression patterns of selected TFs projected on the trajectory plots for WT and  Sp1ΔDBD/ΔDBD from 
day 2 of blast culture
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DBD [35]. However, note that this protein differs from 
other Sp family members since it has only one glutamine-
rich domain instead of the 2 found in Sp1 and Sp3, and 
it does not recognise the conventional Sp binding motif 
[36].  Sp1ΔDBD/ΔDBD mice and ESC retain the N-terminal 
portion of the Sp1 protein [7]. Such Sp1 deletion mutants 
promote synergistic activation of promoter constructs 
when co-transfected with full-length Sp1 constructs or 
with Sp4 in Drosophila SL2 cells lacking endogenous 
Sp1 activity [25]. The DBD mutant has been described 
as a super-activator, and it was observed to contribute to 
multimeric Sp1 complexes in in vitro DNA-binding stud-
ies [37]. Note that many Sp1/3 binding sites occur in CG 
island promoters that contain multiple Sp binding motifs, 
providing a surface for multiple protein–protein interac-
tions. We speculate that the activity of the  Sp1ΔDBD pro-
tein to rescue part of the hematopoietic differentiation 
program is due to a transient interaction with other fac-
tors in chromatin that impacts on gene expression. Such 
transient but functional interactions that leave their mark 
behind in chromatin have been observed previously at 
distal elements [38, 39]. However, additional experiments 
are required to address this issue.
The full activity of Sp1 is required for robust 
and coordinated hematopoietic specification
Developmental pathways are regulated by the interplay of 
external signals and intracellular factors and are normally 
highly robust, with cells executing cell fate decisions in a 
highly coordinated fashion within the developing organ-
ism. Many tissue-specific TFs have been shown to be 
essential for the execution of specific cell fates. For exam-
ple, erythroid and megakaryocyte development requires 
the presence of GATA1 [40] and SCL/TAL1 is essential 
to form all blood cells [41]. However, the mechanism by 
which such factors actually execute cell fate decisions is 
still under intensive investigation and debate. The recent 
development of techniques that determine the pattern 
of gene expression in single cells allowed the discovery 
of previously hidden cellular heterogeneity within pop-
ulations as well as lineage infidelity of gene expression 
within individual cells and, most importantly, made it 
possible to follow differentiation trajectories (reviewed 
in [42]). For example, single-cell profiling of hematopoi-
etic stem-  and progenitor populations has revealed a 
continuum of hematopoietic differentiation rather than 
discrete stages of development [43] and highlighted how 
such decisions are perturbed in the absence of specific 
TFs [44].
In the studies published so far, the perturbation of tis-
sue-specific factors generally led to a loss or defect of a 
specific differentiation trajectory such as the complete 
loss of cells undergoing blood development in Tal1-null 
embryos [45] or Tal1-null cells from chimaeric embryos 
[46] or the inability of cells from Cebpa-null embryos to 
enter myelopoiesis [44]. Our results point to an impor-
tant difference between the role of Sp1/3 and tissue-
specific factors since the absence of stable chromatin 
binding of the  Sp1ΔDBD protein makes differentiation 
inherently unstable without disturbing the general trajec-
tories of early cell fate decisions. Such increased destabi-
lisation manifests itself in an increased heterogeneity of 
gene expression within sorted cell populations [3]. Our 
single-cell analysis resolved this heterogeneity into a pro-
found disturbance of the coordination of cell fate deci-
sions within the developing population. This disturbance 
led to the existence of multiple branch points following a 
similar differentiation trajectory, i.e. the timing and coor-
dination of a specific cell fate decision within the blood 
specification trajectory were disturbed. In addition, we 
observed an increase in onset of megakaryopoiesis at the 
expense of definitive erythropoiesis. The expression of 
genes encoding tissue-specific TFs such as RUNX1, GFI1 
or GATA1, capable of regulating such cell fate decisions, 
followed the path of the disturbed trajectory in  Sp1ΔDBD/
ΔDBD cells. This behaviour indicates that while these genes 
are expressed in the correct cells and cell fate decisions 
are preserved, the robustness of this developmental path-
way is diminished. This notion is also consistent with the 
absence of major differences in cell type-specific chroma-
tin states of WT and  Sp1ΔDBD/ΔDBD cells, meaning that 
within the developing population the correct chromatin 
transitions between ESC and FLK1+ cells take place, and 
this holds true for both promoter and distal sites (data 
not shown). Since Sp1 sites are enriched in promoters, 
we therefore propose that Sp1 and Sp3 are involved in 
setting up a stable promoter structure that is capable of 
interacting with distal elements in a coordinated fashion. 
In  Sp1ΔDBD/ΔDBD cells, these interactions are destabilised, 
introducing a stochastic element into differentiation. As 
the cells approach the terminally differentiated state, the 
accumulation of deregulation events and further desta-
bilisation prevent the execution of differentiation past a 
certain point.
Conclusions
Our results explain why the phenotype of the original 
 Sp1ΔDBD/ΔDBD mouse is highly heterogeneous with devel-
opment blocked at various early stages [7] and why the 
introduction of the same allele in late precursor cells such 
as myeloblast/monocytes has no effect on differentiation 
[3]. Sp1/Sp3 do not co-localise with a specific class of fac-
tors at distal elements but cooperate with distal elements 
bound by factors specific for each cell type. Consist-
ent with this notion, the defect of Sp1 leads to multiple 
abnormalities in many tissues in the mouse. Our data are 
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consistent with the idea that Sp1 and Sp3 are essential 
elements of coordinated and robust developmental pro-
cesses. We propose that other general and ubiquitously 
expressed transcriptional regulators generate similar 
phenotypes with development becoming uncoordinated 
and unstable, thus setting the stage for further aberra-
tions such as developmental defects and cancer.
Methods
Mouse ESC culture
WT,  Sp1ΔDBD/ΔDBD and  Sp3−/− cells [3, 7, 8] as well as A17 
2Lox ESC (a gift from Michael Kyba) were maintained in 
ESC maintenance media: DMEM (Sigma D6546), sup-
plemented with 15% FCS, 100 units/ml penicillin and 
100 µg/ml streptomycin, 1 mM sodium pyruvate, 1 mM 
glutamine, 0.15 mM MTG, 25 mM HEPES buffer,  103 U/
ml ESGRO (Millipore), 1x non-essential amino acids 
(Sigma) on primary mouse embryonic fibroblast (MEF) 
feeder cells. ESC were grown in the absence of feeder 
cells for two passages prior to differentiation.
In vitro differentiation of mouse ESC
In vitro differentiation of ESC was performed as previ-
ously described [3, 47, 48]. More information can be 
found in Additional file 1.
Cell population sorting
HE1, HE2 and progenitor populations for RNA-seq and 
ATAC-seq were prepared at day 2 of blast culture by cell 
sorting according to surface marker expression. Floating 
and adherent cells were harvested and combined before 
staining with KIT-APC (BD Pharmingen 553356), CD41-
PE-Cy7 (ebioscience 25-0411) and Tie2-PE (ebioscience 
12-5987) antibodies in MACS buffer. After washing, 
cells were separated on a FACS Aria cell sorter (BD Bio-
sciences) into HE1 (KIT+, CD41−, Tie2+); HE2 (KIT+, 
CD41+, Tie2+) and progenitor (KIT+, CD41+, Tie2−) 
cell populations according to surface marker expression 
as indicated.
CRISPR deletion of Sp1 DBD in ESC
Guide RNA sequences targeting the Sp1 DNA-bind-
ing domain (Additional file  1: Fig.  S1a) were designed 
using the CRISPR Design Tool by the Zhang laboratory 
[49, 50]. CRISPR guide 1: 5′-TAT ACT TTG CCG CAT 
CCT; CRISPR guide 2: 5′-TTG CAT CCC GGG CTT AGT 
. Annealed double-stranded oligos with compatible ends 
were cloned into plasmid pSpCas9(BB)-2A-GFP (PX458) 
(a gift from Feng Zhang—Addgene #48138) at the BbsI 
site [21, 51].
A17 2Lox murine ESC were transfected with two 
pX458 plasmids, expressing either CRISPR guide 1 or 
CRISPR guide 2 using the Amaxa P3 4D-Nucleofector kit 
(Lonza), according to manufacturer’s guidelines. Trans-
fected cells were seeded onto gelatine-coated dishes. 
GFP expressing cells were purified by cell sorting, and 
single cells were seeded into 96-well plates coated with 
MEFs. GFP + single cell clones were expanded and tested 
for disruption of the Sp1 DBD by PCR of genomic DNA 
using the following primers: FW-5′-TGG CAC ACA TAC 
CTT TAA TCCT and Rev-5′-ACC TGG GAT GAG ATA 
AAT GCTG. The product obtained from WT DNA was 
1564 bp, whereas successful deletion of the target region 
resulted in a product of 496 bp.
Overexpression of Sp1 in ESC CRISPR clones
Sp1ΔDBD/ΔDBD and  Sp1−/− ES cells were co-transfected 
with a PiggyBac (PB) transposase expression vector 
(PL623) [52] and a PiggyBac vector containing the cod-
ing sequence of human Sp1 (PB-PGK-SP1-2A-mCherry) 
using Amaxa nucleofection. Cells were sorted for 
mCherry expression 48 h after transfection. Sorted cells 
were grown on MEFs for approximately 5  days, after 
which individual clones were picked and expanded. Full-
length Sp1 expression was then assayed by qPCR analysis 
and Western blotting. Once positive clones were identi-
fied, the capacity of clones to express Flk1 during in vitro 
differentiation of EBs was measured.
Macrophage release assay
Macrophage release assays were performed essentially 
as previously described [3]. Briefly, ESC were trypsinised 
and allowed to form EB by plating in base methylcellulose 
(Stem Cell Technologies M3134) supplemented with 10% 
FCS, 100  units/ml penicillin and 100  µg/ml streptomy-
cin, 1  mM glutamine, 0.15  mM MTG, 10  µg/ml insulin 
(Sigma), 5% IL-3 conditioned media, 100  units/ml IL-1 
(Peprotech) and 25  ng/ml recombinant mouse M-CSF 
(R&D Systems), at a cell concentration previously deter-
mined to give similar numbers of EB. EB were counted 
after at least 14 days, and the number of EB surrounded 
by a halo of macrophages were determined.
EryP assay
EryP assays were performed essentially as previously 
described [3], and further details can be found in Addi-
tional file 1.
ChIP‑seq
ChIP-seq libraries were prepared using the Kapa Hyper 
Prep kit according to manufacturer’s instruction and as 
previously described [53]. More information on ChIP 
and ChIP-seq can be found in Additional file 1.
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RNA‑seq library preparation
RNA was isolated from cells at each stage of the differ-
entiation protocol as described previously (ESC, Flk1+, 
HE1, HE2 and progenitor) [3]. RNA-seq libraries were 
prepared from two biological replicates for each sam-
ple as described previously [53]. The Tru-Seq Stranded 
Total RNA kit (Illumina) was used to prepare libraries 
according to manufacturer’s instructions. Libraries were 
sequenced in a pool of 12 indexed libraries using a Next-
Seq 500/550 High Output Kit v2 (150 cycles) for paired-
end sequencing (Illumina) at the Genomics Birmingham 
sequencing facility.
ATAC‑seq
ATAC-seq was performed in duplicate, on 50,000 cells 
per sample isolated from each stage of the differentia-
tion protocol (ESC, Flk1+ cells). ATAC-seq libraries were 
prepared essentially as described [54, 55], and more 
detail can be found in Additional file  1. Libraries were 
sequenced in a pool of 12 indexed libraries using a Next-
Seq 500/550 High Output Kit v2 (150 cycles) for paired-
end sequencing (Illumina) at the Genomics Birmingham 
sequencing facility.
Single‑cell RNA‑seq
Single-cell suspensions of E14 WT and E14  Sp1ΔDBD/ΔDBD 
cells were sorted for Kit expression at day 2 of blast cul-
ture prior to loading 4000 single cells of each population 
on a Chromium Single Cell Instrument (10X Genom-
ics). Library generation for single-cell RNA-seq was 
performed as a service by the Genomics Birmingham 
Sequencing Facility using the Chromium Single Cell 3′ 
Library and Gel Bead Kit v2 (10X Genomics). Libraries 
were subjected to paired-end sequencing on an Illumina 
NextSeq 500/550 sequencer according to 10X Genomics 
recommended cycle parameters.
Protein gels and western blotting
Protein extracts in Laemmli buffer were separated on 
4–20% gradient pre-cast gels (Bio-Rad) and transferred 
to nitrocellulose using either Turbo transfer packs (Bio-
Rad) with a semi-dry blotter (Bio-Rad) or by using wet 
transfer to nitrocellulose in 0.1 mM CAPS/10% methanol 
transfer buffer. Blots were blocked with 4% milk powder 
in 0.1% TBS-Tween prior to antibody incubation. Anti-
bodies used were: Sp1, Millipore 07-645; Sp3, Santa Cruz 
sc365220; GAPDH, Abcam ab8245; H3, Abcam ab1791.
Bioinformatic analysis
Details about the bioinformatic analysis of genome-wide 
data sets are described in Additional files 1 and 5.
Additional files
Additional file 1. Supplemental Methods and Figures.
Additional file 2. Dataset 1 ‑ Covariance analysis of RNA‑seq data.
Additional file 3. Dataset 2 ‑ Grouping analysis of RNA‑seq data and 
ChIP‑seq data.
Additional file 4. Dataset 3 ‑ scRNA‑seq cell cluster markers
Additional file 5. Sequencing data list
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